SHU 454

Drug Profile

SHU 454

Alternative Names: Echovist

Latest Information Update: 21 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Contrast media; Polysaccharides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Cardiovascular disorders

Most Recent Events

  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
  • 19 Sep 2003 No development reported - Phase-III for Ultrasound in Japan (IV-injection)
  • 24 Nov 1998 A study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top